首页> 外文期刊>American Journal of Neurodegenerative Disease >Select non-coding RNA in blood components provide novel clinically accessible biological surrogates for improved identification of traumatic brain injury in OEF/OIF Veterans
【24h】

Select non-coding RNA in blood components provide novel clinically accessible biological surrogates for improved identification of traumatic brain injury in OEF/OIF Veterans

机译:血液成分中非编码RNA的选择提供了新颖的临床可替代的生物替代物,可改善OEF / OIF退伍军人颅脑损伤的鉴定

获取原文
       

摘要

This study was designed to identify clinically accessible molecular biomarkers of mild traumatic brain injury (mTBI) that could be used to help identify returning Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) Veterans who are suffering from the effects of mTBI. While analyzing the expression profile of small non-coding RNAs in peripheral blood mononuclear cells (PBMCs) from an OEF/OIF veteran study cohort using a high throughput array chip platform, we identified 18 candidate small non-coding RNA biomarkers that are differentially regulated in PBMCs of mTBI compared to non-TBI control cases. Independent quantitative real-time polymerase chain reaction assays confirmed that 13 of these candidate small RNA biomarker species are, indeed, significantly down-regulated in PBMCs of mTBI compared to non-TBI control veteran cases. Based on unsupervised clustering analysis, we identified a 3-biomarker panel which was most able to distinguish mTBI from non-TBI control veteran cases with high accuracy, selectivity and specificity. The majority of mTBI cases in our biomarker study were co-morbid with Post-Traumatic Stress Disorder (PTSD), and thus our non-TBI control cases were selected to match PTSD diagnoses. Therefore, our identified panel of 3 small RNA biomarkers likely represents a biological index selective for mTBI. Outcomes from our studies suggest that additional applications of the clinically accessible small non-coding RNA biomarkers to current diagnostic criteria may lead to improved mTBI detection and more sensitive outcome measures for clinical trials. Future studies exploring the physiological relevance of mTBI biomarkers will also provide a better understanding of the biological mechanisms underlying mTBI and insights into novel therapeutic targets for mTBI.
机译:这项研究旨在确定轻度创伤性脑损伤(mTBI)的临床可得分子生物学标志物,这些标志物可用于帮助识别遭受mTBI影响的返回伊拉克行动(OIF)和持久行动(OEF)退伍军人。在使用高通量阵列芯片平台分析来自OEF / OIF退伍军人研究队列的外周血单核细胞(PBMC)中小的非编码RNA的表达谱的同时,我们鉴定了18种候选非编码RNA生物标志物,它们在与非TBI对照病例相比,mTBI的PBMC。独立的实时定量聚合酶链反应分析证实,与非TBI退伍军人案例相比,mTBI PBMC中确实有13种候选小RNA生物标记物被显着下调。基于无监督的聚类分析,我们确定了一个3-biomarker小组,最能区分mTBI和非TBI对照退伍军人病例,具有较高的准确性,选择性和特异性。在我们的生物标志物研究中,大多数mTBI病例与创伤后应激障碍(PTSD)并存,因此我们选择了非TBI对照病例以符合PTSD诊断。因此,我们鉴定的3个小RNA生物标记物组可能代表对mTBI有选择性的生物指标。我们研究的结果表明,将可临床使用的小的非编码RNA生物标志物进一步应用到当前的诊断标准中,可能会改善mTBI的检测水平,并为临床试验提供更为敏感的结果指标。未来研究mTBI生物标志物的生理相关性的研究也将提供对mTBI潜在生物学机制的更好理解,以及对mTBI新型治疗靶点的见识。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号